Seres Therapeutics Inc share price logo

Seres Therapeutics Inc

NASDAQ: MCRB

Small Cap

$7.55

-0.45

(-5.65%)

Live

as on

Seres Therapeutics Inc Stock Performance

as on May 8, 2026 at 4:07 am IST

  • Day's Low

    Day's High

    $7.42
    $8.00
    downward going graph

    1.72%

    Downside

    5.96%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.53
    $29.98
    downward going graph

    13.51%

    Downside

    297.09%

    Upside

    downward going graph

Seres Therapeutics Inc share price movements today

Previous Close
$8.00
Open
$7.97
Volume
265.3K
Day's Low - High
$7.42 - $8.00
52 Week Low - High
$6.53 - $29.98

Seres Therapeutics Inc Historical Returns

1 Month Return
-9.6 %
3 Month Return
-42.69 %
1 Year Return
-3.5 %
3 Year Return
-93.23 %
5 Year Return
-98.07 %

Seres Therapeutics Inc Stock Fundamentals & Key Indicators

Check Seres Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$72.2M

EPS (TTM)

-8.23

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.92%

PE Ratio (TTM)

0

PEG Ratio

-0.11

EBITDA

-89.8M

Revenue (TTM)

789.0K

Profit Margin

721.93%

Return On Equity TTM

19.64%

Seres Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Seres Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$72.2M-98.07%NA721.93%
BUY$40.5B130.77%76.3212.55%
NA$32.5BNA70.895.37%
BUY$108.5B98.9%25.3835.51%
BUY$75.6B45.15%17.629.65%

Stock Returns calculator for Seres Therapeutics Inc Stock including INR - Dollar returns

The Seres Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Seres Therapeutics Inc investment value today

Current value as on today

₹1,01,306

Returns

₹1,306

(+1.31%)

Returns from Seres Therapeutics Inc Stock

-₹8,926 (-8.93%)

Dollar Impact

₹10,232 (+10.23%)

Analyst Recommendation on Seres Therapeutics Inc Stock

Based on 13 analysts

BUY

76.92%

Buy

15.38%

Hold

7.69%

Sell

Based on 13 analysts, 76.92% of analysts recommend a 'BUY' rating for Seres Therapeutics Inc. Average target price of $22

Seres Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Seres Therapeutics Inc.

What analysts predicted

65.68%UPSIDE

Target Price

$22

Current Price

$7.55

Analyzed by

13 Analysts

Target

$22.00

Seres Therapeutics Inc target price $22, a slight upside of 65.68% compared to current price of $7.55. According to 13 analysts rating.

Indian Investors' Interest in Seres Therapeutics Inc Stock

Search interest for Seres Therapeutics Inc Stock has increased by 38% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:38% versus previous 30 day period

Seres Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
-
-
-
5
-
-
0
0
0
Gross Profit
0
-1
-1
-1
2
-3
-1
-13
14
-
Operating Income
-39
-34
-28
-29
-28
-27
-24
-22
-19
-20
EBITDA
-35
-30
-24
-49
-14
33
-18
9
-17
-20
Interest Expense
4
4
3
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
1
1
0
-
Income Before Tax
-41
-32
-26
-51
-15
32
-19
8
-15
-19
Income Tax Expense
-2
1
0
-
-
-
-
-
-
-
Net Income
-41
-40
-32
88
-15
32
-19
8
-15
-19
Net Profit Margin
-64450.00%
0.00%
0.00%
0.00%
-262.45%
0.00%
0.00%
2337.32%
-3501.14%
-5562.29%

Seres Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
21
32
28
34
33
144
7
126
-
0
Gross Profit
-60
-57
28
34
-57
144
6
125
-3
-3
Operating Income
-92
-91
-100
-71
-88
-64
-179
-195
-121
-93
EBITDA
-88
-82
-92
-62
-77
-56
-170
-181
-120
-89
Interest Expense
0
1
1
0
2
2
6
13
-
-
Depreciation
-
7
7
7
6
5
6
6
5
4
Income Before Tax
-91
-89
-98
-70
-89
-65
-183
-190
-125
5
Income Tax Expense
2
-1
1
-6
-2
-4
3
14
0
-
Net Income
-91
-89
-98
-70
-89
-65
-250
-113
0
5
Net Profit Margin
-420.74%
-278.44%
-350.03%
-203.68%
-268.33%
-45.25%
-3509.50%
-90.02%
0.00%
721.93%

Seres Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-40
-32
88
-15
32
-19
8
-15
-19
Operating Cash Flow
-35
-39
-34
-38
26
-13
2
-14
-16
Investing Cash Flow
0
1
141
0
0
0
0
0
-
Financing Cash Flow
18
-
-110
1
1
-
0
12
0
Change in Cash
-16
-38
-4
-37
28
-13
2
-1
-15

Seres Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-89
-98
-70
-89
-65
-250
-113
0
5
Operating Cash Flow
-75
-62
-76
-93
6
-228
-117
-148
1
Investing Cash Flow
56
112
-30
-158
64
82
10
142
0
Financing Cash Flow
0
0
86
303
1
129
71
-90
13
Change in Cash
-18
49
-20
50
71
-16
-35
-96
14

Global Institutional Holdings in Seres Therapeutics Inc

Funds
Holdings
Morgan Stanley - Brokerage Accounts
0.26%
The Goldman Sachs Group Inc
0.15%
Marshall Wace Asset Management Ltd
1.39%
Geode Capital Management, LLC
0.89%
Geode Capital Management, LLC
0.94%

Insights on Seres Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 25.4% return, outperforming this stock by 118.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, BeOne Medicines Ltd has given 34.9% return, outperforming this stock by 38.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 8.20M → -19.91M (in $), with an average decrease of 158.4% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, MCRB stock has moved down by -42.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 438.0K → 358.0K (in $), with an average decrease of 18.3% per quarter

About Seres Therapeutics Inc

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
OrganisationSeres Therapeutics Inc
Headquarters101 Cambridgepark Drive, Cambridge, MA, United States, 02140
IndustryBiotechnology
CEOMr. Richard N. Kender B.S., M.B.A.
E-voting on sharesClick here to vote

Key Management of Seres Therapeutics Inc

Name

Title

Mr. Chris McChalicher

Executive VP & CTO

Dr. Dennis M. Walling M.D.

Senior VP of Clinical Development & Head of Clinical Research

Ms. Ann Kurowski

Senior Vice President of Regulatory Affairs

Mr. Richard N. Kender B.S., M.B.A.

Interim CEO & Executive Chair

Dr. Matthew R. Henn Ph.D.

President & Chief Scientific Officer

Mr. Thomas J. DesRosier Esq., J.D.

Executive VP, Chief Legal Officer & Secretary

Ms. Kelly Brady M.S.

Executive VP & COO

FAQs

What is Seres Therapeutics Inc share price today?

Seres Therapeutics Inc share price today is $7.55 as on . Seres Therapeutics Inc share today touched a day high of $8 and a low of $7.42.

What is the 52 week high and 52 week low for Seres Therapeutics Inc share?

Seres Therapeutics Inc share touched a 52 week high of $29.98 on and a 52 week low of $6.53 on . Seres Therapeutics Inc stock price today i.e. is trending at $7.55,which is 74.82% down from its 52 week high and 15.62% up from its 52 week low.

What is Seres Therapeutics Inc's market capitalisation today?

Seres Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Seres Therapeutics Inc Stock (MCRB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Seres Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Seres Therapeutics Inc Shares that will get you 0.1987 shares as per Seres Therapeutics Inc share price of $7.55 per share as on May 7, 2026 at 10:37 pm IST.

What is the minimum amount required to buy Seres Therapeutics Inc Stock (MCRB) from India?

Indian investors can start investing in Seres Therapeutics Inc (MCRB) shares with as little as ₹94.24 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹942.40 in Seres Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Seres Therapeutics Inc share’s latest price of $7.55 as on May 7, 2026 at 10:37 pm IST, you will get 1.3245 shares of Seres Therapeutics Inc. Learn more about fractional shares .

What are the returns that Seres Therapeutics Inc has given to Indian investors in the last 5 years?

Seres Therapeutics Inc stock has given -98.07% share price returns and 29.81% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?